Ultragenyx Pharmaceutical Inc. (RARE) 42.74 $RARE
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 31, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President
GlobeNewswire - Wed Jul 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, effective August 25, 2014. In this role, Dr. Agarwal will provide strategic leadership and direction to Clinical Operations, Clinical Development, Regulatory Affairs, Biometrics, Pharmacovigilance, and Non-Clinical Research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's CEO, and will serve on the Senior Management Team.
Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.
Ultragenyx concludes public offering of 2.32m common shares, including exercise of underwriters' option
M2 - Tue Jul 15, 8:19AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) revealed on Monday the completion of its public offering of 2,319,951 shares of common stock.
Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Jul 14, 12:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its public offering of 2,319,951 shares of common stock at a price to the public of $40.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 302,602 additional shares of common stock. Ultragenyx is selling 1,613,879 shares of its common stock in this offering and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx is not receiving any proceeds from the sale of any shares sold by the selling stockholders. Ultragenyx estimates net proceeds from the offering to be approximately $60.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
Ultragenyx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jul 09, 12:34AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx will not receive any proceeds from the sale of any shares sold by the selling stockholders. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an aggregate of an additional 302,602 shares of the company's common stock at the public offering price, less the underwriting discount.
Why Ultragenyx Pharmaceutical Inc. Stock Slumped
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ultragenyx Pharmaceutical , a...
Ultragenyx to issue 2.017m common shares in public offering
M2 - Tue Jul 08, 6:38AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) said on Monday that it plans to start a public offering of 2,017,349 shares of its common stock.
Ultragenyx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Jul 07, 3:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced an underwritten public offering of 2,017,349 shares of its common stock. The offering is expected to consist of 1,311,277 shares to be offered by Ultragenyx and 706,072 shares to be offered by selling stockholders. In addition, the company and the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an aggregate of an additional 302,602 shares of common stock at the public offering price, less the underwriting discount. Ultragenyx will not receive any proceeds from the sale of any shares sold by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU
GlobeNewswire - Tue Jul 01, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
This Week in Biotech: MannKind's "Finally" Moment and Vertex's Breathtaking Data
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 28, 11:59AM CDT
With the SPDR S&P Biotech Index up 48% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
'Fast Money' Recap: Rangebound Treasury Yields
at The Street - Fri Jun 27, 4:00AM CDT
The trading panel discussed Treasury yields, stock prices and whether to buy Nike.
North Bay Life Science Alliance Mobilizes as California's Bay Area Biotech Sector Soars
Business Wire - Wed Jun 25, 10:00AM CDT
The North Bay Life Science Alliance (NBLSA), a collaborative of public and private institutions in California's North Bay, (just north of San Francisco and consisting of Marin, Napa, Solano and Sonoma counties), today officially launched an initiative to nurture the growth and acceleration of the life science sector in the region. Chris Stewart, Chairman and CEO of the NBLSA, presented the initiative this morning to attendees of the 2014 BIO International Convention in San Diego.
Why Ultragenyx Pharmaceutical Inc. Shares Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 24, 2:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ultragenyx Pharmaceutical , a...
Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
GlobeNewswire - Tue Jun 24, 11:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness. The data was presented at the 2014 ICE/ENDO joint meeting of The Endocrine Society and The International Congress of Endocrinology in Chicago.
'Mad Money' Lightning Round: Globalstar Is a Real Winner
at The Street - Sat Jun 21, 2:53PM CDT
Cramer prefers Federal Realty over Kite Realty Group, Rangold over Yamana Gold and regrets not being more aggressive on Prudential Financial.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Jun 20, 7:18PM CDT
Cramer will be watching Chinese economic data, company earnings and other things to get investors excited next week.
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 31, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President
GlobeNewswire - Wed Jul 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, effective August 25, 2014. In this role, Dr. Agarwal will provide strategic leadership and direction to Clinical Operations, Clinical Development, Regulatory Affairs, Biometrics, Pharmacovigilance, and Non-Clinical Research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's CEO, and will serve on the Senior Management Team.
Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.
Ultragenyx concludes public offering of 2.32m common shares, including exercise of underwriters' option
M2 - Tue Jul 15, 8:19AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) revealed on Monday the completion of its public offering of 2,319,951 shares of common stock.
Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Jul 14, 12:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its public offering of 2,319,951 shares of common stock at a price to the public of $40.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 302,602 additional shares of common stock. Ultragenyx is selling 1,613,879 shares of its common stock in this offering and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx is not receiving any proceeds from the sale of any shares sold by the selling stockholders. Ultragenyx estimates net proceeds from the offering to be approximately $60.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
Ultragenyx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jul 09, 12:34AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx will not receive any proceeds from the sale of any shares sold by the selling stockholders. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an aggregate of an additional 302,602 shares of the company's common stock at the public offering price, less the underwriting discount.
Why Ultragenyx Pharmaceutical Inc. Stock Slumped
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ultragenyx Pharmaceutical , a...
Ultragenyx to issue 2.017m common shares in public offering
M2 - Tue Jul 08, 6:38AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) said on Monday that it plans to start a public offering of 2,017,349 shares of its common stock.
Ultragenyx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Jul 07, 3:30PM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced an underwritten public offering of 2,017,349 shares of its common stock. The offering is expected to consist of 1,311,277 shares to be offered by Ultragenyx and 706,072 shares to be offered by selling stockholders. In addition, the company and the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an aggregate of an additional 302,602 shares of common stock at the public offering price, less the underwriting discount. Ultragenyx will not receive any proceeds from the sale of any shares sold by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU
GlobeNewswire - Tue Jul 01, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
This Week in Biotech: MannKind's "Finally" Moment and Vertex's Breathtaking Data
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 28, 11:59AM CDT
With the SPDR S&P Biotech Index up 48% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
'Fast Money' Recap: Rangebound Treasury Yields
at The Street - Fri Jun 27, 4:00AM CDT
The trading panel discussed Treasury yields, stock prices and whether to buy Nike.
North Bay Life Science Alliance Mobilizes as California's Bay Area Biotech Sector Soars
Business Wire - Wed Jun 25, 10:00AM CDT
The North Bay Life Science Alliance (NBLSA), a collaborative of public and private institutions in California's North Bay, (just north of San Francisco and consisting of Marin, Napa, Solano and Sonoma counties), today officially launched an initiative to nurture the growth and acceleration of the life science sector in the region. Chris Stewart, Chairman and CEO of the NBLSA, presented the initiative this morning to attendees of the 2014 BIO International Convention in San Diego.
Why Ultragenyx Pharmaceutical Inc. Shares Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 24, 2:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ultragenyx Pharmaceutical , a...
Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
GlobeNewswire - Tue Jun 24, 11:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness. The data was presented at the 2014 ICE/ENDO joint meeting of The Endocrine Society and The International Congress of Endocrinology in Chicago.
'Mad Money' Lightning Round: Globalstar Is a Real Winner
at The Street - Sat Jun 21, 2:53PM CDT
Cramer prefers Federal Realty over Kite Realty Group, Rangold over Yamana Gold and regrets not being more aggressive on Prudential Financial.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Jun 20, 7:18PM CDT
Cramer will be watching Chinese economic data, company earnings and other things to get investors excited next week.
